Home › FDA rejects Amarin appeal on Vascepa trial design, shares slump
 

Keywords :   


FDA rejects Amarin appeal on Vascepa trial design, shares slump

2014-01-22 11:50:08| Biotech - Topix.net

Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug.

Tags: design trial shares appeal

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Atlantic Tropical Weather Outlook
30.09Eastern North Pacific Tropical Weather Outlook
30.09Does Chinese investment benefit or damage Ireland?
29.09Tropical Depression Twelve Public Advisory Number 1
29.09Summary for Tropical Depression Twelve (AT2/AL122024)
29.09Tropical Depression Twelve Wind Speed Probabilities Number 1
29.09Tropical Storm Joyce Forecast Discussion Number 10
29.09Tropical Depression Twelve Forecast Discussion Number 1
More »